{
    "title": "Children with TB cannot wait: MSF urges countries to roll out shorter treatment ",
    "modified_at": "2026-11-17 09:50:25",
    "published_at": "2026-11-17 08:25:00",
    "url": "https://msf-switzerland.prezly.com/children-with-tb-cannot-wait-msf-urges-countries-to-roll-out-shorter-treatment",
    "short_url": "http://prez.ly/Wbqe",
    "culture": "de_CH",
    "language": "DE",
    "slug": "children-with-tb-cannot-wait-msf-urges-countries-to-roll-out-shorter-treatment",
    "body": "<p><strong>New MSF study supports roll-out of 4-month treatment for non-severe* tuberculosis (TB) in children in routine healthcare settings </strong> </p><p style=\"text-align: justify\">At the Union World Conference on Lung Health in Rio de Janeiro, M&eacute;decins Sans Fronti&egrave;res (MSF) released the outcomes from a study conducted in Uganda and the Philippines* showing that the World Health Organization (WHO)-recommended 4-month treatment for children with non-severe tuberculosis (TB) can be successfully rolled-out in routine primary healthcare settings. MSF calls on governments, donors and global health partners to move beyond policy adoption and accelerate the implementation of this child-friendly treatment regimen while strengthening diagnosis, prevention and care for all children affected by TB. </p><p style=\"text-align: justify\">The study demonstrates that up to 74% of the children with TB overall and up to 89% in primary healthcare settings are eligible for the shorter regimen, with implementation being feasible with high treatment success rates. This would offer a more person-centred approach to care while reducing the burden of treatment on children, their families and health systems. </p><p style=\"text-align: left\">Despite WHO recommending the 4-month regimen since 2022, uptake has been slow in many high-burden countries. One important challenge has been the need to identify children with non-severe TB who can safely benefit from this shorter treatment, a process that requires clinical assessment and, where available, chest X-ray (CXR) evaluation. The new MSF findings provide practical evidence that these challenges can be overcome in routine programme settings. </p><p style=\"text-align: left\">&ldquo;The 4-month treatment regimen for children with non-severe, drug-susceptible TB uses the same medicines, including child-friendly formulations, but substantially reduces the burden on children and caregivers,&rdquo; said Valentina Carnimeo, Principal Investigator of MSF multi-country TB study. &ldquo;Fewer months of treatment means fewer clinic visits, less disruption to family life, lower costs for caregivers and health systems, and fewer days exposed to potential adverse effects. The evidence is clear: countries can confidently implement this regimen in routine care, and children should not have to wait longer to benefit from it&rdquo;. \u200b \u200b </p><p style=\"text-align: left\">In this prospective study involving 214 children receiving care in health facilities in Uganda and the Philippines, nearly three-quarters (74%) were identified as eligible for the 4-month regimen at the start of treatment. Treatment outcomes were highly positive, with 95% of children successfully completing treatment. Healthcare workers and caregivers welcomed the shorter treatment, citing fewer clinic visits and a reduced burden on families. However, challenges remain, including limited access to chest X-rays, gaps in healthcare worker training and high staff turnover. </p><p style=\"text-align: left\">&ldquo;Our experience of implementing the four-month TB treatment regimen for children shows that it can be successfully introduced into routine care, leaving no reason to delay its wider roll-out,&rdquo; said Dr Maria Namulwana, Study Coordinator, MSF/Epicentre Uganda. &ldquo;But to make this a reality for more children, governments must go beyond updating guidelines and invest in training healthcare workers, strengthening diagnostic services, ensuring access to child-friendly medicines and supporting families throughout treatment.&rdquo; </p><p style=\"text-align: left\">TB remains the world&#039;s deadliest infectious disease, with children being hit hard. As per <a href=\"https://www.who.int/publications/i/item/9789240126480\" target=\"_blank\" rel=\"noreferrer noopener\"><u>WHO&rsquo;s 2026 Global TB Report</u></a>, half of the children under 5 years old have missed TB diagnosis in 2025 and could not access treatment in 2025*, a statistic that has not improved from previous years. </p><p style=\"text-align: left\">&ldquo;Every three minutes, a child dies of TB. We cannot keep leaving children behind when effective medical tools are already within reach, including reducing treatment duration for children with non-severe TB from 6 months to 4 months&rdquo;, said Dr Ana Paula Cavalheiro, Leader of global TB platform of MSF. \u200b &ldquo;It is high time governments and donors step up and ensure that children can be diagnosed early and receive the best possible treatment and care, no matter where they live.&rdquo; </p><p>&nbsp;</p><p>&nbsp;</p><p style=\"text-align: left\"><strong>Notes to editors </strong></p><p>PDFs of the study being presented at the Union Conference in two sessions</p><a href='https://cdn.uc.assets.prezly.com/94922b60-9708-4e17-85d1-6fd226d63570/-/inline/no/msf-get-it-done-implementing-the-4-month-regimen-for-non-severe-childhood-tuberculosis-in-uganda-and-the-philippines.pdf' class='release-content-attachment' id='attachment-94922b60-9708-4e17-85d1-6fd226d63570' data-type='attachment' data-track='Story File Download' data-placement='content' data-id='94922b60-9708-4e17-85d1-6fd226d63570'>\n    <span class='release-content-attachment__icon'>\n        <svg class=\"icon icon-download\">\n                <use xlink:href=\"#icon-download\"></use>\n            </svg>\n    </span>\n    <span class='release-content-attachment__details'>\n        <strong class='release-content-attachment__title'>MSF - GET IT DONE Implementing the 4-month regimen for non-severe childhood tuberculosis in Uganda and the Philippines.pdf</strong>\n        <em class='release-content-attachment__subtitle'>138 KB</em>\n    </span>\n</a><a href='https://cdn.uc.assets.prezly.com/0a419a4d-dda2-48f7-a83e-f8e15f29539d/-/inline/no/msf-findings-from-uganda-and-the-philippines-cross-country-insights-on-implementing-the-4-month-pediatric-tb-regimen.pdf' class='release-content-attachment' id='attachment-0a419a4d-dda2-48f7-a83e-f8e15f29539d' data-type='attachment' data-track='Story File Download' data-placement='content' data-id='0a419a4d-dda2-48f7-a83e-f8e15f29539d'>\n    <span class='release-content-attachment__icon'>\n        <svg class=\"icon icon-download\">\n                <use xlink:href=\"#icon-download\"></use>\n            </svg>\n    </span>\n    <span class='release-content-attachment__details'>\n        <strong class='release-content-attachment__title'>MSF - FINDINGS FROM UGANDA AND THE PHILIPPINES Cross-country insights on implementing the 4 month pediatric TB regimen.pdf</strong>\n        <em class='release-content-attachment__subtitle'>334 KB</em>\n    </span>\n</a><p style=\"text-align: left\">Non-severe tuberculosis is a milder form of tuberculosis where the disease is limited and has not caused extensive damage to the lungs or spread widely in the body. \u200b </p><p style=\"text-align: left\">Drug susceptible tuberculosis is a form of tuberculosis that responds to the standard first line medications and is not resistant to key drugs. \u200b </p><p style=\"text-align: left\">The WHO-recommended four-month regimen for children with non-severe, drug-susceptible TB consists of two months of isoniazid, rifampicin and pyrazinamide, with or without ethambutol, followed by two months of isoniazid and rifampicin (2HRZ(E)/2HR). It uses the same medicines as the standard six-month regimen (2HRZ(E)/4HR), including child-friendly dispersible tablets. </p><p style=\"text-align: left\">MSF has been working to improve TB care for children in 12 countries, through its <a href=\"https://www.msf.org/tactic-tuberculosis-children\" target=\"_blank\" rel=\"noreferrer noopener\"><u>Test, Avoid and Cure TB in Children (TACTiC) initiative</u></a>, by putting the latest WHO recommendations into practice and generating evidence to support their wider adoption. </p><div class=\"release-content-contact\" id=\"contact-a008312d-fabb-4f71-81fd-d918ec6eb4c4\">\n    \n    <div class=\"release-content-contact__details\">\n        <strong class=\"release-content-contact__name\">Jeremias Schnyder</strong>\n        <em class=\"release-content-contact__description\">Team Public Engagement</em>\n        <ul class=\"release-content-contact__details-list\"><li class=\"release-content-contact__details-list-item\"><a href=\"mailto:jeremias.schnyder@geneva.msf.org\"  class=\"release-content-contact__details-list-item-link\" title=\"jeremias.schnyder@geneva.msf.org\"><svg class=\"icon icon-paper-plane release-content-contact__details-list-item-icon\">\n                <use xlink:href=\"#icon-paper-plane\"></use>\n            </svg>jeremias.schnyder@geneva.msf.org</a></li>\n<li class=\"release-content-contact__details-list-item\"><a href=\"tel:+41 44 385 94 58\"  class=\"release-content-contact__details-list-item-link\" title=\"+41 44 385 94 58\"><svg class=\"icon icon-phone release-content-contact__details-list-item-icon\">\n                <use xlink:href=\"#icon-phone\"></use>\n            </svg>+41 44 385 94 58</a></li></ul>\n    </div>\n</div><p>&nbsp;</p>",
    "attachments": [
        {
            "description": "",
            "extension": "pdf",
            "url": "https://cdn.uc.assets.prezly.com/94922b60-9708-4e17-85d1-6fd226d63570/-/inline/no/msf-get-it-done-implementing-the-4-month-regimen-for-non-severe-childhood-tuberculosis-in-uganda-and-the-philippines.pdf"
        },
        {
            "description": "",
            "extension": "pdf",
            "url": "https://cdn.uc.assets.prezly.com/0a419a4d-dda2-48f7-a83e-f8e15f29539d/-/inline/no/msf-findings-from-uganda-and-the-philippines-cross-country-insights-on-implementing-the-4-month-pediatric-tb-regimen.pdf"
        }
    ],
    "contacts": [
        {
            "name": "Jeremias Schnyder",
            "company": null,
            "description": "Team Public Engagement",
            "email": "jeremias.schnyder@geneva.msf.org",
            "website": null,
            "address": null,
            "telephone": "+41 44 385 94 58",
            "mobile": null,
            "twitter": null,
            "facebook": null,
            "linkedin": null,
            "instagram": null
        }
    ],
    "author": {
        "first_name": "Jeremias",
        "last_name": "Schnyder"
    },
    "format_version": 6
}